Physician profile
Brian M Barbara
NPI 1982232880
$1,143.08
in general payments reported to CMS, 2019-2025
23 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $164 · 2024: $640 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $337.59 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $98.45 | 2023-2025 | Vraylar |
| Pfizer INC. | $97.98 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $84.39 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $82.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $45.36 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $43.48 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $32.22 | 2023-2024 | Veozah |
| Amgen INC. | $31.41 | 2024-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $28.68 | 2024-2025 | Kisunla, Jardiance, Zepbound |
| Dexcom, INC. | $26.25 | 2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $24.60 | 2025 | Daybue |
| Mylan Specialty L.P. | $23.56 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $23.42 | 2023 | |
| Alnylam Pharmaceuticals INC. | $21.85 | 2024 | Givlaari |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $21.03 | 2025 | Mcot |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.38 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $19.26 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $18.70 | 2024 | Gemtesa |
| Corcept Therapeutics | $18.51 | 2024 | Korlym |
| Viiv Healthcare Company | $15.84 | 2024 | Apretude |
| Seqirus USA INC | $15.20 | 2025 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $13.61 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Barbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.